# BCPC earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/BCPC) · [Earnings tab](https://www.lopjlb.com/stock/BCPC?tab=earnings) Updated: 2026-10-23T08:07:30 Quarters analyzed: 8 ## Cross-quarter narrative Across 8 calls for BCPC, management tone moved from +0.80 (2024 Q3) to +0.80 (2026 Q2). Latest guidance stance: vague. Latest desk line: Balchem delivered record Q2 2026 results with 11% sales growth to $284M, 13% adj EBITDA growth to $78M, broad-based segment strength, refinanced credit facility to $650M, and continued share repurchases. ## Latest CallCard · Q2 Balchem delivered record Q2 2026 results with 11% sales growth to $284M, 13% adj EBITDA growth to $78M, broad-based segment strength, refinanced credit facility to $650M, and continued share repurchases. **Guidance:** vague — No explicit quantitative guidance provided on call; management expresses confidence in continued growth and margin performance. **Tone:** mgmt 0.8 · Q&A pressure 0.3 · divergence 0.5 Prepared remarks emphasize 'extremely pleased', 'record quarterly consolidated sales', '28th consecutive quarter of year-over-year growth in adjusted EBITDA', and confidence in continued growth and margin performance. ### Demand visibility Healthy broad-based demand across all segments. Human Nutrition & Health driven by supplementation and healthier product trends; Animal Nutrition & Health driven by rumen-protected nutrient adoption and European monogastric recovery post antidumping duties; Specialty Products driven by performance gases and plant nutrition. ### Margins / costs Gross margin expanded 10 bps to 36.5%; adj EBITDA margin 27.4%. Margin expansion driven by sales growth and manufacturing efficiencies, partially offset by higher input costs from Middle East conflict; A&H margin improved despite higher input costs due to mitigating actions and operating leverage. ### Capital allocation Refinanced credit facility to $650M (2031 maturity), repurchased $29M stock in Q2 ($114M TTM). Credit facility upsized from $550M, spread improved 10 bps; variable rate ~4.5% (SOFR + spread); $150M drawn at quarter end; leverage 0.3x net debt/EBITDA; disciplined buyback reflects commitment to shareholder returns. ### Milestones - **Optifolin+ launch** [delivered]: Internal development with external partner, launched approximately one year ago. - **VitaCholine acquisition (CureMark)** [delivered]: Acquired different technology to expand nutrient portfolio. - **European antidumping duties implementation** [delivered]: Effective Jan 1, 2026; monogastric volumes returning and price recovery improving each quarter. - **Credit facility refinancing** [delivered]: Increased capacity to $650M, extended maturity to 2031, improved pricing grid. - **Share repurchase program** [on_track]: $29M repurchased in Q2, $114M trailing 12 months. - **Ruminant business growth** [on_track]: Grew ~20% YoY in Q2, almost entirely volume-driven. - **Consumer engagement marketing model** [on_track]: Scalable model via influencers, sports partnerships (soccer/football), and digital mediums. - **28th consecutive quarter adj EBITDA growth** [delivered]: Record adjusted EBITDA of $78M, up 12.6% YoY. ### Fears / risks - **Input cost inflation**: Higher manufacturing input costs related to the conflict in the Middle East. - **Interest rate exposure**: Variable rate credit facility (~4.5% SOFR + spread) resets with Fed rate changes. - **Tax rate volatility**: Effective tax rate increased to 22.8% from 21.9% due to lower stock-based compensation benefits; full-year estimate 22.5-23%. - **Policy dependence in Europe**: European monogastric recovery reliant on continued enforcement of EU antidumping duties. - **Consumer trend shifts**: H&H growth dependent on sustained demand for healthier, high-protein, high-fiber, lower-sugar products. ### Key quotes > “We were extremely pleased with our second quarter performance reported this morning, which was once again driven by healthy broad-based growth across all three of our reporting segments.” — Theodore L. Harris > “The second quarter of 2026 was our 28th consecutive quarter of year-over-year growth in adjusted EBITDA.” > “We wanna make sure there is already good existing sound science behind the products that we are bringing in.” > “In Europe, where we filed for antidumping and successfully got that through, and that started as of January 1 or end of December of 2025. So we have been in that environment for six months now. We have really seen the return of that” ## Quarter one-liners - **2026 Q2:** Balchem delivered record Q2 2026 results with 11% sales growth to $284M, 13% adj EBITDA growth to $78M, broad-based segment strength, refinanced credit facility to $650M, and continued share repurchases. - **2026 Q1:** Balchem delivered record Q1 2026 results with 8.1% sales growth, 12.1% adjusted EBITDA growth, and 27th consecutive quarter of YoY EBITDA growth, while flagging petrochemical inflation and Middle East conflict as risks to Animal Nutrition margins. - **2025 Q4:** — - **2025 Q3:** Balchem posted record Q3 sales and earnings, highlighted strong demand across segments, announced a 2027 capacity expansion, and said debt reduction will hinge on future M&A activity. - **2025 Q2:** Balchem posted record Q2 2025 results with strong demand across human, animal and specialty segments, announced a new micro‑encapsulation plant to double capacity, and reaffirmed a positive outlook despite tariff and timing uncertainties. - **2025 Q1:** Balchem posted record Q1 2025 sales, earnings and margins, citing strong segment performance and confidence in navigating trade‑related tariff impacts. - **2024 Q4:** Balchem delivered record Q4 and FY2024 results across all segments with strong margin expansion, debt reduction to 0.6x leverage, and new product launches; management sees momentum into 2025 but flags tariff uncertainty as key risk to margins. - **2024 Q3:** Balchem delivered record Q3 earnings with strong HNH and Specialty Products growth offsetting ANH softness; new product launches and improving M&A pipeline support outlook, though margins expected to moderate. ## Theme arcs - **Management tone** (stable): Δ mgmt=+0.00 ## Fear persistence - **european feed market competition** [resolved]: 2024 Q3 - **animal nutrition & health demand recovery** [resolved]: 2024 Q3 - **margin sustainability** [resolved]: 2024 Q3 - **m&a execution risk** [resolved]: 2024 Q3 - **raw material cost inflation** [resolved]: 2024 Q3 - **tariff and trade policy uncertainty** [resolved]: 2024 Q4 - **input cost inflation** [recurring]: 2024 Q4, 2026 Q1, 2026 Q2 - **margin rate pressure** [resolved]: 2024 Q4 - **foreign tax rate increase** [resolved]: 2024 Q4 - **monogastric market weakness** [resolved]: 2024 Q4 ## Guidance path 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/BCPC`